Investigating Interleukin-34 Levels in Periodontal Disease
Effect of Non-surgical Periodontal Therapy on Interleukin-34 Level in Gingival Crevicular Fluid in Patients With Periodontal Disease (Controlled Clinical Trial)
NA · Ain Shams University · NCT05962567
This study is testing if measuring a specific protein in the gums can help understand how well nonsurgical treatment works for people with stage II periodontitis compared to healthy individuals.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 20 Years to 50 Years |
| Sex | All |
| Sponsor | Ain Shams University (other) |
| Locations | 1 site (Cairo) |
| Trial ID | NCT05962567 on ClinicalTrials.gov |
What this trial studies
This study aims to examine the levels of Interleukin 34 (IL-34) in the gingival crevicular fluid of patients with stage II periodontitis before and after nonsurgical periodontal therapy, comparing these levels to those in healthy individuals. It will also analyze the correlation between changes in IL-34 levels and periodontal health parameters following treatment. The research focuses on understanding the inflammatory processes involved in periodontal disease and how they can be managed through therapy.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 20-50 with stage II periodontitis who have at least 20 natural teeth and can comply with plaque control instructions.
Not a fit: Patients who smoke, are pregnant or lactating, have systemic diseases affecting therapy outcomes, or have undergone recent periodontal treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients with periodontal disease by identifying biomarkers that indicate treatment response.
How similar studies have performed: While the specific focus on IL-34 in periodontal disease may be novel, similar studies investigating inflammatory markers in periodontal therapy have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with stage II Periodontitis. * Both genders aged from 20-50 years * Minimum 20 natural teeth excluding third molars * Good compliance with the plaque control instructions following initial therapy. * Availability for follow-up and maintenance program. Exclusion Criteria: .•Smokers * Pregnant and lactating females. * Systemic diseases that could affect the outcome of the therapy (According to Cornell Medical Index-Health Questionnaire). * Patients taking antibiotics, anti-inflammatory, and immunosuppressive therapy during the preceding 3 months before the start of the trial and during the study. * Patients who have undergone any periodontal therapy in the last 6 months * Vulnerable groups of patients e.g. (handicapped patients).
Where this trial is running
Cairo
- Faculty of Dentistry-Ain Shams University — Cairo, Egypt (RECRUITING)
Study contacts
- Study coordinator: Nada S. Ahmed
- Email: nadazidan1271994@gmail.com
- Phone: 00201060041571
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Periodontal Disease Stage 2